Related coverage linked through entity extraction aliases.
Jul 27, 2026
New research and guidelines highlight the promise and perils of AI in medicine, from a Dartmouth study showing AI-drafted patient messages can introduce errors, to the Israel Medical Association's new position paper. Regulatory responses vary, with FDA guidance and state laws still evolving.
Jul 23, 2026
The FDA approved Tzield for stage 3 type 1 diabetes, and the therapy was given to children in Canada for the first time. Research also advanced on engineered islets and stem-cell treatments.
Jul 23, 2026
FDA approved Novartis' Fabhalta for IgAN to slow kidney function decline. Phase III ALIGN data for Vanrafia showed ~34% slower eGFR decline vs placebo and were published in The Lancet.
Jul 25, 2026
Moderna shares fell 11% on Friday, eyeing their worst week since August 2025 after a June surge. An FDA panel voted 9-0 for its mRNA-1010 flu vaccine, with a decision due by August 5.
Jul 07, 2026
Novo Nordisk partners with OpenAI to speed drug discovery, with pilots by 2026. AI is moving beyond hype into pharma R&D, reflected in major collaborations and new FDA guidance.
Jul 24, 2026
The FDA launched two pilots to boost domestic manufacturing: PreCheck selected seven companies for earlier engagement, and a CVM pilot prioritizes animal drug applications with US-made ingredients.
Jul 11, 2026
MassBio's Align Summit 2026 returns October 15 in Boston with 50+ startups and AI drug discovery tracks. The SITC EU summit adds a pre-clinical models panel, and UCLA's Cell-Cell Symposium 2026 tackles single-cell spatial data challenges.
Jul 22, 2026
FDA granted traditional approval to Novartis' Fabhalta (iptacopan) for IgA nephropathy. Phase 3 APPLAUSE-IgAN data showed eGFR decline slowed by 48% versus placebo over two years.
Aug 05, 2026
Magnesium supplements can interact with antibiotics and bone-loss drugs, reducing their effectiveness. High doses may cause diarrhea, nausea, and low blood pressure. Experts advise talking to a health care provider before use.
Aug 06, 2026
Cocrystal Pharma advanced CDI-988 in a Phase 1b norovirus study and received FDA Fast Track designation. Nuvation Bio reported $18.5 million in IBTROZI net product revenues and presented updated TRUST trial data. Nautilus Biotechnology progressed its proteomics platform toward commercialization, maintaining a cash runway through 2027.
Jul 21, 2026
Crispr Therapeutics AG trades at $47.78 with a $4.78B market cap, while Moderna trades at $61.82 with a $25.06B market cap, about 5.2 times larger. Both face losses, but CRISPR's Casgevy approval and Moderna's pipeline advances shape divergent analyst outlooks.
Jul 31, 2026
Life Biosciences has treated the first patient with ER-100, a cell-rejuvenating gene therapy for glaucoma. The FDA-approved Phase 1 trial will assess safety in up to 18 patients.
Aug 05, 2026
Insilico Medicine named ISM9528 as its 31st AI-driven preclinical pain candidate, published a target discovery study for a rare sinonasal cancer, and advanced partnerships with MSK and Takeda. The company is also presenting oncology programs at AACR 2026.
Aug 04, 2026
Cardiol Therapeutics announced that Phase II MAvERIC results in recurrent pericarditis were accepted for publication in JAHA. The company also provided updates on its Phase III MAVERIC trial, published ARCHER trial results, and CRD-38 development.
May 08, 2026
Recent studies highlight progress in monoclonal antibodies against measles, Lyme disease, and Epstein-Barr virus. A Phase I Lyme antibody trial showed lasting protection, while preclinical antibodies blocked EBV and measles infection.
Aug 08, 2026
The FDA approved Tregzi (Orca-T), a first-of-its-kind regulatory T cell-based immunotherapy, for adults with blood cancers undergoing matched donor stem cell transplants. Approval was based on the PRECISION-T trial, in which 78% of treated patients achieved chronic GVHD-free survival at one year versus 38.4% with standard transplant.
Jul 20, 2026
The FDA has cleared Telomir Pharmaceuticals' IND for Telomir-Zn in advanced or metastatic triple-negative breast cancer. The company plans to initiate a first-in-human Phase 1/2 trial in the first half of 2026.
May 31, 2026
Positive Phase 3 VOXZOGO results in hypochondroplasia; FDA sNDA submission planned in Q3. Q4 2025 revenue rose 17% to $874.6M, beating estimates; EPS missed. Q1 2026 results due May 4.
Jun 02, 2026
Polaryx Therapeutics selected a CRO for its SOTERIA Phase 2 basket trial evaluating PLX-200 in four lysosomal storage disorders. The trial is planned to start in the first half of 2026, following an FDA safe-to-proceed letter received in October 2025.
Aug 08, 2026
CAR-T therapy reaches 150 patients in Ireland and expands into autoimmune trials for lupus and MS. Kyverna's miv-cel nears FDA approval for stiff person syndrome, and new research links gene variants to CAR-T outcomes.
